![JEREMY LEVIN PHILLIP FROST TEVA PHARMACEUTICALS Editorial Stock Photo - Stock Image | Shutterstock | Shutterstock Editorial JEREMY LEVIN PHILLIP FROST TEVA PHARMACEUTICALS Editorial Stock Photo - Stock Image | Shutterstock | Shutterstock Editorial](https://editorial01.shutterstock.com/preview-440/6012420a/813eb337/Shutterstock_6012420a.jpg)
JEREMY LEVIN PHILLIP FROST TEVA PHARMACEUTICALS Editorial Stock Photo - Stock Image | Shutterstock | Shutterstock Editorial
![Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates, Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,](https://c8.alamy.com/comp/2CX4Y3N/teva-pharmaceutical-industries-new-ceo-jeremy-levin-speaks-during-a-news-conference-in-tel-aviv-may-9-2012-teva-pharmaceutical-industries-posted-a-40-percent-jump-in-quarterly-profit-that-beat-estimates-boosted-by-robust-sales-of-its-own-branded-products-and-generic-medicines-in-the-united-states-reutersnir-elias-israel-tags-business-health-2CX4Y3N.jpg)
Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,
![Teva Chairman Phillip Frost (C) stands with outgoing CEO Shlomo Yanai (R) and incoming CEO Jeremy Levin during a news conference in Tel Aviv January 2, 2012. Teva Pharmaceutical Industries, the world's Teva Chairman Phillip Frost (C) stands with outgoing CEO Shlomo Yanai (R) and incoming CEO Jeremy Levin during a news conference in Tel Aviv January 2, 2012. Teva Pharmaceutical Industries, the world's](https://c8.alamy.com/compes/2cwn2w4/teva-chairman-phillip-frost-c-stands-with-outgoing-ceo-shlomo-yanai-r-and-incoming-ceo-jeremy-levin-during-a-news-conference-in-tel-aviv-january-2-2012-teva-pharmaceutical-industries-the-worlds-largest-generics-drugmaker-said-on-monday-that-yanai-would-step-down-as-president-and-chief-executive-officer-in-may-yanai-will-be-replaced-by-levin-a-former-senior-executive-at-bristol-myers-squibb-teva-said-in-a-statement-reuters-nir-elias-israel-tags-business-drugs-society-health-2cwn2w4.jpg)
Teva Chairman Phillip Frost (C) stands with outgoing CEO Shlomo Yanai (R) and incoming CEO Jeremy Levin during a news conference in Tel Aviv January 2, 2012. Teva Pharmaceutical Industries, the world's
![Amazon | Biotechnology in the Time of COVID-19: Commentaries from the Front Line | Levin, Jeremy M. | Biological Sciences Amazon | Biotechnology in the Time of COVID-19: Commentaries from the Front Line | Levin, Jeremy M. | Biological Sciences](https://images-na.ssl-images-amazon.com/images/I/71B8WkuLthL.jpg)